# Development and validation of a rapid, single-step reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) system potentially to be used for reliable and high-throughput screening of COVID-19

1 Minghua Jiang<sup>1\*</sup>, Weihua Pan<sup>2\*</sup>, Amir Aratehfar<sup>3\*</sup>, Wenjie Fang<sup>2</sup>, Liyan Ling<sup>4</sup>, Hua Fang<sup>5</sup>,

2 Farnaz Daneshnia<sup>3</sup>, Jian Yu<sup>1</sup>, Wanqing Liao<sup>2</sup>, Hao Pei<sup>6#</sup>, Xiaojing, Li<sup>7#</sup>, Cornelia Lass-Flörl<sup>8</sup>

- <sup>3</sup> <sup>1</sup> Department of Laboratory Medicine, The Second Affiliated Hospital and Yuying Children's
- 4 Hospital of Wenzhou Medical University, Wenzhou, China;
- <sup>5</sup> <sup>2</sup> Shanghai Key Laboratory of Molecular Medical Mycology, Shanghai Institute of Mycology,
- 6 Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China;
- <sup>3</sup> Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands;
- <sup>4</sup> Department of Laboratory Medicine, Pinghu Second People's Hospital, Zhejiang, China;
- <sup>5</sup> Department of Laboratory Medicine, Pudong New Area People's Hospital, Shanghai, China;
- <sup>6</sup> Department of Laboratory Medicine, Wuxi No. 5 People's Hospital, Jiangsu, China;
- <sup>7</sup> Department of Dermatology, Affiliated Hospital of Hebei University of Engineering, Hebei, China;
- <sup>8</sup> Institute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck,
- 13 Austria
- 14 \*Minghua Zhu, Weihua Pan and Amir Aratehfar equally contributed to this study.

# 15 **\* Correspondence:**

- 16 Xiaojing Li, Tel: +8615000632735, Fax: 86-021-81885502, Email: zlmdsh@126.com
- 17 Hao Pei, Tel: 86-0510-68585555, Fax: 86-0510-68585555, Email: peihao1008@126.com
- 18 Keywords: RT-LAMP, COVID-19, qRT-PCR, and SARS COV-2
- 19 Abstract
- 20 Objectives: Development and validation of a single-step and accurate reverse transcriptase loop-
- 21 mediated isothermal amplification technique (RT-LAMP) for rapid identification of SARS COV-2
- 22 relative to commercial quantitative reverse transcriptase real-time PCR (qRT-PCR) assays to allow
- 23 prompt initiation of proper medical care and containment of virus spread.
- 24

**Running Title** 

25 Methods: Primers showing optimal *in-silico* features were subjected to analytical sensitivity and 26 specificity to assess the limit of detection (LOD) and cross-reaction with closely- and distantly-27 related viral species, and clinically prominent bacterial and fungal species. In order to evaluate the 28 clinical utility, our RT-LAMP was subjected to a large number of clinical samples, including 213 29 negative and 47 positive patients, relative to two commercial quantitative RT-PCR assays.

30

31 **Results:** The analytical specificity and sensitivity of our assay was 100% and 500 copies/ml when 32 serial dilution performed in both water and sputum. Subjecting our RT-LAMP assay to clinical 33 samples showed a high degree of specificity (99.5%), sensitivity (91.4%), positive predictive value 34 (97.7%), and negative predictive value (98.1%) when used relative to qRT-PCR. Our RT-LAMP 35 assay was two times faster than qRT-PCR and is storable at room temperature. A suspected case that 36 later became positive tested positive using both our RT-LAMP and the two qRT-PCR assays, which 37 shows the capability of our assay for screening purposes.

38

39 **Conclusions:** We present a rapid RT-LAMP assay that could extend the capacity of laboratories to 40 process two times more clinical samples relative to qRT-PCR and potentially could be used for high-41 throughput screening purposes when demand is increasing at critical situations.

42

#### 43 1 Introduction

44 A new virus causing pneumonia-like infection, COVID-19, which was found in Wuhan, Hubei 45 Province, China, and to be linked to a seafood market has caused a serious crisis worldwide (1). 46 Almost two months after the first report, COVID-19 severe outbreaks were reported in numerous 47 countries and became a public health priority in the world (World Health Organization, Situation 48 Report 48). As of March 17, 2020, COVID-19 cases are found in 150 countries/regions and infected 49 167,515 patients, among whom 6,606 died (World Health Organization, Situation Report 56). The 50 latest phylogenetic analysis studies designated the etiologic agent of COVID-19, SARS COV-2 (2).

51 The virulent nature of this virus and its high rate of transmissibility warrants robust, rapid, sensitive, 52 specific, and quantitative diagnostic tools to supplement clinical symptoms aiding clinicians to 53 confidently rule in and rule out patients. Moreover, such a diagnostic tool will help with preventing 54 spread of virus by identifying the infected cases and can monitor the health status of infected patients 55 by quantifying the viral load. Center for Disease Control was the first to develop a quantitative 56 reverse transcriptase real-time PCR (RT-PCR), which later became the gold standard technique 57 (https://www.cdc.gov/coronavirus/2019-ncov/about/testing.html). Subsequently, a Chinese group 58 used a RNA-based metagenomics next generation sequencing (mNGS) to diagnose the viral RNA 59 from the clinical samples of two patients (3). However, the requirement for advanced technology and 60 skilled personnel and long turn-around time (24 hours) are not feasible for local and referral 61 laboratories. Therefore, a colorimetric loop mediated isothermal amplification, also known as LAMP, 62 was developed to obviate the need for expensive technologies, e.g. real-time PCR and NGS, as well 63 as to shorten the turn-around time to up to 40 minutes (4). However, this assay was a qualitative one 64 and also only the swab samples from limited number of patients (n=7) were included for testing (4). 65 Most recently a newer generation of single step RT-LAMP were developed to detect SARS COV-2, 66 but these assays were not challenged with real clinical samples obtained from COVID-19 positive 67 patients (5, 6). Therefore, we developed a sensitive, specific, and rapid RT-LAMP assay and its 68 performance was challenged by an extensive number of confirmed COVID-19 (n=47) and negative 69 patients (n=213) relative to qRT-PCR assays approved by two Chinese Food and Drug 70 Administration (qRT-PCR NMPA). Altogether, we present a rapid and reliable diagnostic tool that 71 potentially could be deployed for high-throughput screening applications in referral and local 72 laboratories.

## 73 2 Materials and methods

## 74 Target selection

**Running Title** 

75 According to Guidelines for prevention and control of Covid-19 (Fourth Edition) issued by National 76 Health Commission of the PRC on 2020.2.26, open reading frame 1ab (ORF1ab) or nucleocapsid 77 protein (N) were recommended for designing diagnostic assays detecting SARS-HCoV-2 from 78 clinical samples. Therefore, ORF1ab and N sequences of SARS-Cov-2, its close related coronavirus 79 species (HCoV-NL63, HCoV-OC43, HCoV-229E and HCoV-HKU1), and other viral species, 80 namely Adenovirus, Respiratory syncytial virus A, Human parainfluenza 2 virus, Human 81 parainfluenza 3 virus, H1N1 influenza virus, H5N1 influenza virus, H7N9 influenza virus, H9N2 82 influenza virus, Mycoplasma pneumoniae and Influenza B virus, were downloaded from GenBank 83 (https://www.ncbi.nlm.nih.gov/genbank/) to select the most specific target region. Genenious 84 v11.1.14 was used for alignment analysis and to find the most specific region for designing LAMP 85 primers. LAMP Designer (PREMIER Biosoft International, San Francisco, CA) was used for primer 86 design. Designed primers were subjected to BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi) and the 87 specific candidates were used for analytical sensitivity and specificity testing (Table 1). Primers were 88 synthesized by Sangon Biotech Co., Ltd. (Shanghai, China).

## 89 Analytical sensitivity and specificity testing

90 Analytical sensitivity and specificity testing was performed in a P2 lab and in order to mimic the real 91 viral particles we purchased pseudotyped SARS-CoV-2 assay system containing ORF1ab part 92 sequence, N gene and E gene (DAAN gene Co. Ltd. Guangzhou, China). RNA of pseudotyped virus 93 were extracted using EZ-10 Spin Column Viral Total RNA Extraction Kit (Sangon Biotech Co.,Ltd. 94 Shanghai, China). Serial dilutions with the magnitude of log10 containing  $50*10^{6}$  cell/ml to  $50*10^{0}$ 95 cell/ml pseudotyped virus were performed to determine the limit of detection (LOD). Serial dilution 96 testing was performed in both RNase/DNase free molecular grade water and sputum sample collected 97 from a COVID-19 negative healthy individual. Reproducibility of our LAMP assay (linearity= $R^2$ ) 98 value) was assessed by separate serial dilution testing on three occasions, each performed in duplicate.

Signal intensity and the time to obtain decent amplification curves were recorded and  $R^2$  values 99 100  $\geq 0.98$  were considered reliable amplification.

101 Specificity testing included nucleic acid of HCoV-OC43, HCoV-HKU1, HCoV-229E, HCoV-102 NL63, Adenovirus, Respiratory syncytial virus A, Human parainfluenza 2 virus, Human 103 parainfluenza 3 virus, H1N1 influenza virus, H5N1 influenza virus, H7N9 influenza virus, H9N2 104 influenza virus, Mycoplasma pneumoniae, Influenza B virus (Bdsbiotech Co. Ltd, Guangzhou, 105 China). Moreover, HeLa cells (TechStar Co. Ltd, Jiangsu, China) and genomic DNA of clinically 106 prominent bacteria or fungal species, including *Staphylococcus aureus*, *Mycobacterium tuberculosis*, 107 Legionella pneumophila, Candida albicans, Candida glabrata, Candida tropicalis, Aspergillus 108 fumigatus, Cryptococcus neoformans were used for specificity testing (provided by Shanghai 109 Institute of Medical Mycology, Shanghai Changzheng hospital). LAMP incubation time was set to 60 110 minutes to observe both limit of detection and cross-reactivity (LAMP conditions are mentioned in 111 clinical evaluation section). The reaction endpoint time was set in a way to detect the lowest possible 112 copy number of virus without any cross-reaction.

**Evaluating LAMP assay tolerance against wide range of inhibitors** 

114 Clinical samples obtained from patients contain a wide range of inhibitors impairing the efficacy of 115 diagnostic assay. Therefore, the tolerance of our LAMP assay was assessed when 500 copy/ml of 116 simulated viral particles were mixed with human blood, mucin,  $\beta$ -adrenergic bronchodilator, Tamiflu,

117 dexamethasone, adrenaline.

## **Clinical validation** 118

113

119 Clinical validation engaged two clinical centers, namely The Second Affiliated Hospital and Yuying 120 Children's Hospital of Wenzhou Medical University, Wenzhou, China (Center one), and the Wuxi

121 Infectious Diseases Hospital, Wuxi, China (Center two). Each center used a different qRT-NMPA 122 assay as a gold standard technique. SARS-CoV-2 kit from Shanghai BioGerm Medical 123 Biotechnology Co. Ltd, (NMPA approval number 20203400065, with LOD of 1000 copies/ml, Ct 124 cut-off 38), and a kit from DAAN Gene Co., Ltd (NMPA approval number 20203400063, with LOD 125 of 500 copies/ml, cut off Ct value of 40) were used in center one and center two, respectively. 126 Positive patients were divided into two groups by physicians, namely suspected and confirmed. 127 Those suspected were isolated and all became positive. The ethics committees of both centers 128 approved the study. Emergency patients (outpatients) with fever of unknown origin or inpatients 129 diagnosed as COVID-19 or other diseases were enrolled and samples such as sputum, swabs and 130 tears were used for evaluation. ABI 7500 were used for amplification and data analysis in both 131 centers.

132 The final LAMP reaction was 25 µl and contained 21.9 µl buffer solution (20 mM Tris-HCl pH 8.8, 133 10 mM (NH4)2SO4, 120 mM KCl, 2 mM MgSO4, 0.1% Tween 20), 8 U Bst DNA polymerase (New 134 England Biolabs (Beijing) ltd, Beijing, China), 0.5 U AMV Reverse Transcriptase (Takara Bio Inc, 135 Dalian, China), 2 µl RNA template, 1.6 µMFIP/BIP primers, 0.2 µM F3/B3 primers, 0.4 µM LF/LB 136 primers, 7 mM MgSO4 (Sangon Biotech Co., Ltd., Shanghai, China), 0.8M betaine (Sangon Biotech 137 Co., Ltd., Shanghai, China), 1.4 mM each dNTP (Takara Bio Inc, Dalian, China), 0.5 µM SYTO-9 138 (Invitrogen Trading, Shanghai) Co., Ltd, Shanghai, China). LAMP reactions were incubated at 63°C 139 for 30 mins in ABI 7500 machine and florescent data were collected each minute. RT-PCR and RT-140 LAMP tested separately by two assessors, final results were recorded and were compared with one 141 another.

## 142 **3 Results and discussion**

143 The whole workflow of our study from *in-silico* analysis to analytical evaluation and clinical 144 validation is depicted in Figure 1. Nine and six LAMP primer systems were designed and evaluated 145 *in-silico*, but only the six primers showed the highest sensitivity and specificity, which used in the 146 next steps (Table 1). Primarily, our assay was meant to be quantitative and it showed an optimal 147 reproducibility when tested in analytical evaluation step using armored viral particle diluted in water ( $\mathbb{R}^2$  value  $\Box 0.99$ ) and sputum sample ( $\mathbb{R}^2$  value  $\Box 0.83$ ). Analytical sensitivity yielded reliable LOD of 148 149 500 copies/ml less than 30 minutes regardless of matrix used for serial dilution (Figure 1). Of note, 150 our assay could detect 50 copies/ml, but some replicates showed unstable amplification. Therefore, 151 we considered the LOD of 500 copies/ml. Analytical specificity was 100% when used a wide range 152 of closely- and distantly-related viral species, prominent fungal and bacterial species, and human 153 DNA. Moreover, analytical evaluation included a wide range of inhibitors and 500 copies of the 154 simulated viral particles were successfully detected below 30 minutes (Figure 1). In order to evaluate 155 the performance of our assay in clinic, we provided our assay and respective instructions to two 156 clinical centers (Figures 1, 2). In total, 168 patients from center 1, among which 35 confirmed 157 COVID-19 cases, and 92 patients from center 2, among which 12 patients were confirmed COVID-158 19 cases, were recruited. One asymptomatic patient tested positive by qRT-PCR (Ct values 37) and 159 by our RT-LAMP was categorized suspected by in-charge physician and few days later became 160 positive. Four patients tested positive by qRT-PCR were negative by our RT-LAMP and one patient 161 tested negative by qRT-PCR was positive by our assay (Figure 1 and Supplementary Table 1). 162 Subsequently, our RT-LAMP assay showed the sensitivity, specificity, negative predictive value, and 163 positive predictive value of 91.4%, 99.5%, 98.1%, and 97.7%, respectively (Supplementary Table 2 164 and 3). The fact that our assay could not detect four positive patients was owing to using 2.5 less 165 RNA input (2 µl) relative to qRT-PCR (5 µl). In the future, we will try to use various RNA input 166 volume (5, 8, and 10 µl) to observe if we could obtain a higher sensitivity. Although our RT-LAMP 167 assay was developed to be quantitative, we could not find any pattern and association between the

D	•	
Run	nina	- L'itla
Null		IIIIC

168 time to positivity by our RT-LAMP assay and the Ct values reported by qRT-PCR when using 169 clinical samples. Therefore, we considered our assay a qualitative one. This fact will show that the analytical valuation should be always accompanied by clinical validation to observe the real 170 171 capabilities of a given assay and that the results obtained in analytical evaluation step are not always 172 reflected in real-life.

173 Our assay has several advantageous compared to qRT-PCR. First, our RT-LAMP assay is two times 174 faster relative to qRT-PCR (Figure 2) and given the optimal diagnostic features could be used as a 175 reliable screening method in local and referral laboratory to keep up with the increasing demand of 176 suspected patients in critical situations. Secondly, our assay does not need the clod chain and could 177 be shipped at room temperature (Figure 2).

178 In conclusion, we present a rapid RT-LAMP assay that allows processing 2 to 2.5 more clinical 179 samples relative to CDC RT-PCR, which is indicative of its capacity to be deployed for high-180 throughput screening applications in local and referral laboratories.

181 We admit that our assay does not has the quantitative aspect of qRT-PCR and its sensitivity requires

182 improvement. These two limitations will be the subject of future investigation. Moreover, we will try

183 to use simple and fast nucleic acid extraction procedures (7) that only uses heat that will further

184 decrease the turn-around-time.

#### 185 **Ethics Statement**

186 The protocol was approved by the Ethics and Research Committee of The Second Affiliated Hospital 187 and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China, and the Wuxi 188 Infectious Diseases Hospital, Wuxi, China

#### 189 Figures

190 Figure 1. Our assay was comprehensively evaluated at three steps, including in-silico analysis, in-191 vitro analytical analysis, and clinical validation.

- 192 Figure 2. Workflow comparison of our RT-LAMP assay relative to qRT-PCR for emergency cases
- 193 (outpatients) and inpatients. Our RT-LAMP assay is 2 to 2.5 times faster than the qRT-PCR assays
- and can be shipped at room temperature.

## 195 Tables

196 Table 1. Primers and probes successfully detected SARS COV-2.

Target loci	Primer name	Primer sequence
Nucleocapsid protein	nCoV-N-F3	CCAGAATGGAGAACGCAGTG
	nCoV-N-B3	CCGTCACCACCACGAATT
	nCoV-N-FIP	AGCGGTGAACCAAGACGCAGGGCGCGATC AAAACAACG
	nCoV-N-BIP	AATTCCCTCGAGGACAAGGCGAGCTCTTCG GTAGTAGCCAA
	nCoV-N-LF	TTATTGGGTAAACCTTGGGGGC
	nCoV-N-LB	TTCCAATTAACACCAATAGCAGTCC

197

## 198 **Conflict of Interest**

199 The authors declare that the research was conducted in the absence of any commercial or financial 200 relationships that could be construed as a potential conflict of interest.

## 201 Author Contributions

202 JMH, PWH and AA participated in primer design, LAMP optimization, data collection, and drafted

203 the manuscript. LXJ and PH participated in designing this study and revising the manuscript. WJF,

LLY, FH participated in collecting clinical samples. All authors contributed to the writing of the final manuscript.

## 206 Funding

- 207 This work was supported by the Shanghai Sailing Program (19YF1448000), the Major National
- 208 R&D Projects of the National Health Department (2018ZX10101003), National Natural Science
- 209 Foundation of China (31770161), Shanghai Science and Technology Committee (grant numbers

**Running Title** 

- 210 17DZ2272900 and 14495800500), Shanghai Municipal Commission of Health and Family Planning
- 211 (2017ZZ01024-001).

### 212 Reference

- 213 Ma X, Ph D, Wang D, Ph D, Xu W, Wu G, Gao GF, Phil D, Tan W, Ph D. 2020. A Novel 1. 214 Coronavirus from Patients with Pneumonia in China, 2019. New England Journal of Medicine 727-215 733.
- 216 2. Wu Y, Ho W, Huang Y, Jin D, Li S, Liu S, Liu X, Oiu J, Sang Y, Wang O, Yuen K, Zheng Z. 217 2020. SARS-CoV-2 is an appropriate name for the new coronavirus. The Lancet 6736:2–3.
- 218 Chen L, Liu W, Zhang Q, Xu K, Ye G, Wu W, Sun Z, Liu F, Wu K, Zhong B, Mei Y, Zhang 3. 219 W, Chen Y. 2020. RNA based mNGS approach identifies a novel human coronavirus from two 220 individual pneumonia cases in 2019 Wuhan outbreak. Emerging microbes & infections 1751.
- 221 4. Zhang Y, Odiwuor N, Xiong J, Sun L, Nyaruaba RO, Wei H, Tanner NA, Tanner N. 2020. 222 Rapid Molecular Detection of SARS-CoV-2 (COVID-19) Virus RNA 2.
- 223 5. Park G, Ku K, Beak S, Kim SJ, Kim S II, Kim B. 2020. Development of Reverse 224 Transcription Loop-mediated Isothermal Amplification (RT-LAMP) Assays Targeting SARS-CoV-225 2.
- 226 6. Lamb LE, Bartolone SN, Ward E, Chancellor MB. 2020. Rapid Detection of Novel 227 Coronavirus (COVID-19) by Reverse Transcription- Loop-Mediated Isothermal Amplification.
- 228 7. Myhrvold C, Freije CA, Gootenberg JS, Abudayyeh OO, Metsky HC, Durbin AF, Kellner 229 MJ, Tan AL, Paul LM, Parham LA, Garcia KF, Barnes KG, Chak B, Mondini A, Nogueira ML, Isern
- 230 S, Michael SF, Lorenzana I, Yozwiak NL, MacInnis BL, Bosch I, Gehrke L, Zhang F, Sabeti PC.
- 231 2018. Field-deployable viral diagnostics using CRISPR-Cas13. Science 360:444–448.
- 232 **Supplementary Material**
- 233 **Appendix Table 1.** Signal intensity and time corresponded to each serial dilution obtained during three separate 234 experiments. Each experiment was performed in duplicate.
- 235 Appendix Table 2. False positive and false negative results reported by our RT-LAMP assay, when compared to 236 qRT-PCR.
- 237 **Appendix Table 3**. Diagnostic feature of our RT-LAMP assay when compared to qRT-PCR.
- 238



**Emergency patient** 

throat swab or sputum taken immediately



Sent to Emergency Laboratory



**o** 5 mins





Sample disinfection

**RNA** extraction

Prepare reagents and sample added



Liquid Reagent























